$RNA

Atrium Therapeutics (Nasdaq: RNA) reported Q2 2026 results for the quarter ended June 30. FDA cleared its IND for ATR 1072 and it launched the Corventis Phase 1/2 trial for PRKAG2 syndrome. Atrium also received a $15 million second milestone payment from Bristol Myers Squibb. Q2 collaboration revenue was $3.0M, R&D $15.3M, G&A $10.3M, cash $263.9M.

Atrium Therapeutics, Inc. (RNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d149126dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Atrium Therapeutics Reports Second Quarter 2026 Financial Results — IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome — — Achieved second milestone payment under global cardiovascular col

24/7 Wall St. lists Thursday analyst calls. JPMorgan upgraded Charles River Laboratories (CRL) to Overweight, target $310. Wolfe raised Global Payments (GPN) to Outperform, target $110. Argus upgraded Roper Technologies (ROP) to Buy, target $450. Piper cut AppLovin (APP) to Neutral, target $385, and HubSpot (HUBS) to Neutral, target $220. Several other upgrades, downgrades, and initiations are noted.

Atrium Therapeutics (RNA) said the FDA cleared its IND for ATR 1072 to start its first precision cardiology program for PRKAG2 syndrome, a rare genetic cardiomyopathy with no approved root-cause therapies. ATR 1072 uses siRNA to silence mutant PRKAG2 mRNA and normalize AMPK activity. A Corventis Phase 1/2 trial will enroll ~37 patients, with first enrollment by end-2026 and proof-of-concept expected in 2H 2027.

Cantor Fitzgerald began coverage of Avidity Biosciences (NASDAQ: RNA) with an “overweight” rating and a $25.00 price target, implying 100.32% upside from the stock’s level. Other analysts cited include Wells Fargo (overweight) and Leerink (outperform), while consensus remains “Hold” with an average target of $66.81. The stock opened at $12.48; on May 14 it reported Q1 EPS of -$0.97 and revenue of $19.64M.

Avidity Biosciences announced the expansion of its RNA therapeutic discovery pipeline, adding new research and development candidates in skeletal muscle and cardiology. The company is leveraging its proprietary AOC platform to target previously untreatable diseases and continues to advance three rare disease programs in Phase 1/2 clinical development for myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD). Avidity also maintains collaborations with Eli Lilly and Company and MyoKardia to further explore its AOC platform's potential.

Avidity Biosciences Inc. reached an all-time high of $72.70, marking a 141.25% increase over the past year, driven by investor confidence in its RNA-based therapies. The company also announced a Managed Access Program for delpacibart zotadirsen for Duchenne muscular dystrophy patients and will be acquired by Novartis for approximately $12 billion ($72 per share). Following the acquisition news, analysts at Chardan Capital Markets and TD Cowen downgraded the stock and adjusted their price targets.

Avidity Biosciences (NASDAQ:RNA) has been downgraded to a "Hold" rating by Evercore ISI, with other firms also cutting ratings, resulting in a consensus "Hold" with an average price target of $69.57. The company missed Q3 EPS estimates, reporting ($1.27) against ($1.05) expected, despite a 420.8% revenue jump to $12.48M. Insiders have also sold approximately $1.5 million worth of shares recently, and the stock is trading near its one-year high.

This article identifies two healthcare stocks, Henry Schein (HSIC) and Avidity Biosciences (RNA), that might concern investors due to their overbought status indicated by a high Relative Strength Index (RSI). Avidity Biosciences recently missed analyst consensus on quarterly losses but beat sales estimates and announced a merger agreement with Novartis, while Henry Schein received an Overweight rating from Barclays. Investors are advised to consider momentum as a key trading criterion when evaluating these stocks.

Franklin Resources Inc. reduced its stake in Avidity Biosciences (NASDAQ:RNA) by 44.0% in Q2, selling 29,465 shares and retaining 37,430 shares valued at approximately $1.06 million. Despite a significant year-over-year revenue increase of 420.8%, Avidity Biosciences remains loss-making with a negative net margin, and its shares are trading near a one-year high with a $10.79 billion market cap. Analysts have a consensus "Hold" rating with a target price of $69.24 for RNA.